Fluidigm Reports Preliminary Q4 Revenues of $21M | GenomeWeb

NEW YORK (GenomeWeb News) — Fluidigm said today that it expects total revenue for the fourth quarter of 2013 to be approximately $21 million, beating consensus analyst estimates of $19.5 million and representing a 34 percent spike compared to Q4 2012 revenues of $15.7 million.

Based on preliminary, unaudited financial data, Fluidigm said that it expected Q4 instrument revenue to be approximately $12 million and consumables revenue to be approximately $8.5 million compared to $9.6 million and $5.8 million, respectively, in the same quarter last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.